CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash flows from operating activities:
Net income/(loss)	$ 2,153	$ (26,836)
Reconciliation of net loss to net cash (used in) provided by operating activities:
Depreciation of fixed assets and leases	182	985
Provision for bad debt	350	85
Provision for write down of inventory	(1,077)	1,394
Stock based compensation	70	491
Amortization of debt costs and debt discount	186	1,704
Amortization of intangible assets	589	741
Non cash lease expense	91	103
Foreign currency exchange (gain)/loss	2,092	1,597
Loss on impairment of intangible assets	24	8,373
Non cash interest expense	3,134	1,984
Gain on debt restructuring	(22,439)	0
Inducement loss	1,889	0
Change in the fair value of derivative liabilities	3,186	1,258
Changes in operating assets and liabilities:
Accounts receivable	1,037	11,637
Inventories	3,590	(8,186)
Prepaid expenses, other current receivables, and assets	365	(58)
Accounts payable and accrued expenses	(6,187)	1,889
Operating liabilities	(109)	(107)
Net cash used in operating activities	(10,874)	(2,946)
Cash flows from investing activities:
Capital expenditures	(47)	(880)
Net cash used in investing activities	(47)	(880)
Cash flows from financing activities:
Proceeds from Term Loan 2023	1,465	0
Proceeds from ATM	34,940	0
Debt issuance costs	(3,986)	0
Principal paid on lease obligation	(4)	(3)
Net cash provided by (used in) financing activities	32,415	(3)
Effect of exchange rate on cash and cash equivalents	104	(651)
Net increase (decrease) in cash, cash equivalents and restricted cash	21,598	(4,480)
Cash, cash equivalents and restricted cash at beginning of period	6,712	16,182
Cash, cash equivalents and restricted cash at end of period	28,310	11,702
Supplemental Cash flow information:
Cash payments for interest	441	388
Cash payments for income taxes	16	34
Non-cash operating, investing and financing transactions:
Acquisition of capital expenditures in accounts payable and accrued expenses	24	183
Capitalized stock compensation in capital expenditures	0	5
Issuance of Series D preferred stock	$ 15,374	$ 0